nach oben

Current Heart Failure Reports

Erschienen in:

26.01.2023

Remote Monitoring of Cardiac Implantable Electronic Devices: What is the Evidence?

verfasst von: Adrian Reinhardt, Rodolfo Ventura

Erschienen in: Current Heart Failure Reports | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review offers an overview of the evidence in diagnostic and therapeutic applications of remote monitoring implantable devices.

Recent Findings

Remote monitoring of cardiac implantable devices has become more and more popular in recent years as healthcare is moving towards a more patient centralized system. For heart failure patients with an ICD or pacemaker, there is controversial evidence regarding improvements in the clinical outcome, e.g., reduction of hospitalization rates or overall mortality. New developments as hemodynamic remote monitoring via measurement of the pulmonary artery pressure are promising technical achievements showing encouraging results. In cardiac remote monitoring of syncope and arrhythmias, implantable loop recorder plays an important role in diagnostic algorithms.

Summary

Although there is controversial evidence according to remote monitoring of implantable devices, its use is rapidly expanding, giving healthcare providers the opportunity to react promptly to worsening of their patients. Adequate evaluation of the data created by remote monitoring systems remains an unsolved challenge of contemporary healthcare services.

McDonagh TA, Metra M, Adamo M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368.CrossRefPubMed

Braunschweig F, Anker SD, Proff J, et al. Remote monitoring of implantable cardioverter-defibrillators and resynchronization devices to improve patient outcomes: dead end or way ahead? Europace. 2019;21:846–55. https://doi.org/10.1093/europace/euz011.CrossRefPubMedPubMedCentral

Kelly SE, Campbell D, Duhn LJ, et al. Remote monitoring of cardiovascular implantable electronic devices in Canada: survey of patients and device health care professionals. CJC Open. 2021;3:391e–399. https://doi.org/10.1016/j.cjco.2020.11.010.CrossRef

Hajduczok AG, Muallem SN, Nudy MS, et al. Remote monitoring for heart failure using implantable devices: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Heart Fail Rev. 2022;27(4):1281–300. https://doi.org/10.1007/s10741-021-10150-5.CrossRefPubMed

Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10):572–80. https://doi.org/10.1016/S0140-6736(17)32520-5.CrossRefPubMedPubMedCentral

Savarese G, Lund LH. Global public health burden of heart failure. Cardiac Failure Review. 2017;3(1):7–11. https://doi.org/10.15420/cfr.2016:25:2.CrossRefPubMedPubMedCentral

Parthiban N, Esterman A, Mahajan R, et al. Remote monitoring of implantable cardioverter-defibrillators: a systematic review and meta-analysis of clinical outcomes. J Am Coll Cardiol. 2015;65:2591–600. https://doi.org/10.1016/j.jacc.2015.04.029.CrossRefPubMed

Varma N, Epstein AE, Irimpen A, et al. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation. 2010;122:325–32. https://doi.org/10.1161/CIRCULATIONAHA.110.937409.CrossRefPubMed

Al-Khatib SM, Piccini JP, Knight D, et al. Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. J Cardiovasc Electrophysiol. 2010;21(5):545–50. https://doi.org/10.1111/j.1540-8167.2009.01659.x.CrossRefPubMed

10.

Guédon-Moreau L, Chevalier P, Marquié C, ECOST trial investigators, et al. Contributions of remote monitoring to the follow-up of implantable cardioverter-defibrillator leads under advisory. Eur Heart J. 2010;31(18):2246–52. https://doi.org/10.1093/eurheartj/ehq203.CrossRefPubMedPubMedCentral

11.

Ranasinghe I, Parzynski CS, Freeman JV, et al. Long-term risk for device-related complications and reoperations after implantable cardioverter-defibrillator implantation: an observational cohort study. Ann Intern Med. 2016;165(1):20–9. https://doi.org/10.7326/M15-2732.CrossRefPubMed

12.

Hawkins NM, Grubisic M, Andrade JG, et al. Long-term complications, reoperations and survival following cardioverter-defibrillator implant. Heart. 2018;104(3):237–43. https://doi.org/10.1136/heartjnl-2017-311638.CrossRefPubMed

13.

Varma N, Michalski J, Epstein AE, et al. Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: the Lumos-T Safely RedUceS RouTine Office Device Follow-Up (TRUST) trial. Circ Arrhythm Electrophysiol. 2010;3(5):428–36. https://doi.org/10.1161/CIRCEP.110.951962.CrossRefPubMed

14.

Watanabe E, Yamazaki F, Goto T, et al. Remote management of pacemaker patients with biennial in-clinic evaluation: continuous home monitoring in the Japanese at-home study: a randomized clinical trial. Circ Arrhythm Electrophysiol. 2020;13(5):e007734. https://doi.org/10.1161/CIRCEP.119.007734.CrossRefPubMedPubMedCentral

15.

Hayashi Y, Takagi M, Kakihara J, et al. A case of unexpected early battery depletion caused by lithium cluster formation in implantable cardioverter-defibrillator. J Cardiol Cases. 2017;15(6):184–6. https://doi.org/10.1016/j.jccase.2017.02.007.CrossRefPubMedPubMedCentral

16.

Aggarwal A, Sarmiento JJ, Charles DR, et al. Accelerated implantable defibrillator battery depletion secondary to lithium cluster formation: a case series. Pacing Clin Electrophysiol. 2016;39(4):375–7. https://doi.org/10.1111/pace.12808.CrossRefPubMed

17.

Pokorney SD, Greenfield RA, Atwater BD, et al. Novel mechanism of premature battery failure due to lithium cluster formation in implantable cardioverter-defibrillators. Heart Rhythm. 2014;11(12):2190–5. https://doi.org/10.1016/j.hrthm.2014.07.038.CrossRefPubMed

18.

Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808–17. https://doi.org/10.1093/eurjhf/hft050.CrossRefPubMed

19.

Bergethon KE, Ju C, DeVore AD, et al. Trends in 30-day readmission rates for patients hospitalized with heart failure: findings from the get with the guidelines-Heart Failure Registry. Circ Heart Fail. 2016;9(6):10.1161. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002594.CrossRef

20.

Chun S, Tu JV, Wijeysundera HC, et al. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail. 2012;5(4):414–21. https://doi.org/10.1161/CIRCHEARTFAILURE.111.964791.CrossRefPubMedPubMedCentral

21.

Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [published correction appears in Eur Heart J. 2010;12(4):416. https://doi.org/10.1093/eurheartj/ehn309.

22.

Glikson M, Nielsen JC, Kronborg MB, ESC Scientific Document Group, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427–520. https://doi.org/10.1093/eurheartj/ehab364.CrossRefPubMed

23.

Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. https://doi.org/10.1161/CIR.0000000000001063.CrossRefPubMed

24.

Kotalczyk A, Kalarus Z, Wright DJ, et al. Cardiac electronic devices: future directions and challenges. Med Devices (Auckl). 2020;13:325–38. https://doi.org/10.2147/MDER.S245625.CrossRefPubMed

25.

Imberti JF, Tosetti A, Mei DA, et al. Remote monitoring and telemedicine in heart failure: implementation and benefits. Curr Cardiol Rep. 2021;23(6):55. https://doi.org/10.1007/s11886-021-01487-2.CrossRefPubMedPubMedCentral

26.

Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841–8. https://doi.org/10.1161/CIRCULATIONAHA.104.492207.CrossRefPubMed

27.

Fang SC, Wu YL, Tsai PS, et al. Heart rate variability and risk of all-cause death and cardiovascular events in patients with cardiovascular disease: a meta-analysis of cohort studies. Biol Res Nurs. 2020;22(1):45–56. https://doi.org/10.1177/1099800419877442.CrossRefPubMed

28.

van Veldhuisen DJ, Braunschweig F, Conraads V, DOT-HF Investigators, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation. 2011;124(16):1719–26. https://doi.org/10.1161/CIRCULATIONAHA.111.043042.CrossRefPubMed

29.

Gardner RS, Singh JP, Stancak B, et al. HeartLogic multisensor algorithm identifies patients during periods of significantly increased risk of heart failure events. Circ Hear Fail. 2018;11:e004669. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004669.CrossRef

30.

Ahmed FZ, Taylor JK, Green C, et al. Triage-HF Plus: a novel device-based remote monitoring pathway to identify worsening heart failure. ESC Hear Fail. 2020;7:108–17. https://doi.org/10.1002/ehf2.12529.CrossRef

31.

Saxon LA, Hayes DL, Gilliam FR, et al. Long term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation. 2010;122:2359–67. https://doi.org/10.1161/CIRCULATIONAHA.110.960633.CrossRefPubMed

32.

DeSimone A, Leoni L, Luzi M, et al. Remote monitoring improves outcome after ICD implantation: the clinical efficacy in the management of heart failure (EFFECT) study. Europace. 2015;17:1267–75. https://doi.org/10.1093/europace/euu318.CrossRef

33.

Guedon-Moreau L, Lacroix D, Sadoul N, et al. A randomized study of remote follow-up of implantable cardioverter defibrillators: safety and efficacy report of the ECOST trial. Eur Heart J. 2013;34:605–14. https://doi.org/10.1093/eurheartj/ehs425.CrossRefPubMed

34.•

Hindricks G, Taborsky M, Glikson M, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN TIME): a randomised controlled trial. Lancet. 2014;384:583–90. https://doi.org/10.1016/S0140-6736(14)61176-4. Important study which showed significant effects of RM on overall mortality.CrossRefPubMed

35.

Klersy C, Boriani G, De Silvestri A, et al. Effect of telemonitoring of cardiac implantable electronic devices on healthcare utilization: a meta-analysis of randomized controlled trials in patients with heart failure. Eur J Heart Fail. 2016;18(2):195–204. https://doi.org/10.1002/ejhf.470.CrossRefPubMed

36.

Boriani G, Da Costa A, Quesada A, et al. Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial. Eur J Heart Fail. 2017;19:416–25. https://doi.org/10.1002/ejhf.626.CrossRefPubMed

37.

Bohm M, Drexler H, Oswald H, et al. Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J. 2016;37:3154–63. https://doi.org/10.1093/eurheartj/ehw099.CrossRefPubMed

38.

Boehmer JP, Hariharan R, Devecchi FG, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE Study. JACC Heart Fail. 2017;5(3):216–25. https://doi.org/10.1016/j.jchf.2016.12.011.CrossRefPubMed

39.•

Hernandez AF, Albert NM, Allen LA, et al. MANAGE-HF Study. Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - phase I evaluation of the integration and safety of the HeartLogic multisensor algorithm in patients with heart failure. J Card Fail. 2022:S1071–9164(22)00483–3. https://doi.org/10.1016/j.cardfail.2022.03.349First phase of important trial suggesting safe and successful integration of remote monitoring into clinical care.

40.

Precision event monitoring for patients with heart failure using HeartLogic (PREEMPT-HF) U.S. National Library of Medicine; Bethesda, MD, USA: 2018. NCT03579641.

41.

Bertini M, Marcantoni L, Toselli T, et al. Remote monitoring of implantable device: should we continue to ignore it? Int J Cardiol. 2016;202:368–77. https://doi.org/10.1016/j.ijcard.2015.09.033.CrossRefPubMed

42.

Burri H. Is there a future for remote cardiac implantable electronic device management? Arrhythm Elektrophysiol Rev. 2017;6:109. https://doi.org/10.15420/aer.2017:10:1.CrossRef

43.

Ono M, Varma N. Remote monitoring for chronic disease management: atrial fibrillation and heart failure. Card Electrophysiol Clin. 2018;10:43–58. https://doi.org/10.1016/j.ccep.2017.11.005.CrossRefPubMed

44.

Zakeri R, Morgan JM, Phillips P, et al. Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM-HF trial. Eur J Heart Fail. 2020;22(3):543–53. https://doi.org/10.1002/ejhf.1709.CrossRefPubMed

45.

Morgan JM, Kitt S, Gill J, et al. Remote management of heart failure using implantable electronic devices. Eur Heart J. 2017;38(30):2352–60. https://doi.org/10.1093/eurheartj/ehx227.CrossRefPubMedPubMedCentral

46.

Amara W, Montagnier C, Cheggour S, et al. Early detection and treatment of atrial arrhythmias alleviates the arrhythmic burden in paced patients: the SETAM study. Pacing Clin Electrophysiol. 2017;40:527–36. https://doi.org/10.1111/pace.13062.CrossRefPubMed

47.

Lima CEB, Martinelli M, Peixoto GL, et al. Silent atrial fibrillation in elderly pacemaker users: a randomized trail using home monitoring. Ann Noninvasive Electrocardiol. 2016;21:246–55. https://doi.org/10.1111/anec.12294.CrossRefPubMed

48.

Jang JP, Lin HT, Chen YJ, et al. Role of remote monitoring in detection of atrial arrhythmia, stroke reduction, and use of anticoagulant therapy. Circ J. 2020;84:1922–30. https://doi.org/10.1253/circj.CJ-20-0633.CrossRefPubMed

49.

Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr Heart Fail Rep. 2009;6(4):287–92. https://doi.org/10.1007/s11897-009-0039-z.CrossRefPubMed

50.••

Abraham WT, Adamson PB, Bourge RC, for the CHAMPION Trial Study Group, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66. https://doi.org/10.1016/S0140-6736(11)60101-3. Results of the pivotal CHAMPION Trial showing efficacy of remote hemodynamic monitoring to reduce heart failure hospitalizations.CrossRefPubMed

51.

Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. CircHeart Fail. 2014;7:935–44. https://doi.org/10.1016/S0140-6736(11)60101-3.CrossRef

52.

Krahnke JS, Abraham WT, Adamson PB, Champion Trial Study Group, et al. Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. J Card Fail. 2015;21:240–9. https://doi.org/10.1016/j.cardfail.2014.12.008.CrossRefPubMed

53.

Shavelle DM, Desai AS, Abraham WT, CardioMEMS Post-Approval Study Investigators, et al. lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS post-approval study. Circ Heart Fail. 2020;13(8):e006863. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006863.CrossRefPubMedPubMedCentral

54.

Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomized trial. Lancet. 2016;387:453–61. https://doi.org/10.1016/S0140-6736(15)00723-0.CrossRefPubMed

55.

Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021;398(10304):991–1001. https://doi.org/10.1016/S0140-6736(21)01754-2.CrossRefPubMed

56.

Cowie MR, Flett A, Cowburn P, Foley P, Chandrasekaran B, Loke I, et al. Real-world evidence in a national health service: results of the UK CardioMEMS HF System Post-Market Study. ESC Heart Fail. 2022;9(1):48–56. https://doi.org/10.1002/ehf2.13748.CrossRefPubMed

57.•

Angermann CE, Assmus B, Anker SD, et al. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European monitoring study for heart failure (MEMS-HF). Eur J Heart Fail. 2020;22:1891–901. https://doi.org/10.1002/ejhf.1943. First study to suggest generalisability of US CardioMEMS findings to rest of western healthcare system.CrossRefPubMed

58.

Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol. 2017;69:2357–65. https://doi.org/10.1016/j.jacc.2017.03.009.CrossRefPubMed

59.

Martinson M, Bharmi R, Dalal N, et al. Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial. Eur J Heart Fail. 2017;19:652–60. https://doi.org/10.1002/ejhf.642.CrossRefPubMed

60.

Störk S, Bernhardt A, Böhm M, et al. Pulmonary artery sensor system pressure monitoring to improve heart failure outcomes (PASSPORT-HF): rationale and design of the PASSPORT-HF multicenter randomized clinical trial. Clin Res Cardiol. 2022;4:1–11. https://doi.org/10.1007/s00392-022-01987-3.CrossRef

61.

Pachulsky R, Cockrell J, Salomon H, et al. Implant evaluation of an insertable cardiac monitor outside the electrophysiology labsetting. PloSOne. 2013;8(8):e71544. https://doi.org/10.1371/journal.pone.0071544.CrossRef

62.

Rogers JD, Sanders P, Piorkowski C, et al. In-office insertion of a miniaturized insertable cardiac monitor: results from the Reveal LINQ In-Office 2 randomized study. Heart Rhythm. 2017;14(2):218–24. https://doi.org/10.1016/j.hrthm.2016.11.001.CrossRefPubMed

63.

Giada F, Bertraglia E, Reimers B, et al. Current and emerging indications for implantable cardiac monitors. Pacing Clin Electrophysiol. 2012;35:1169–78. https://doi.org/10.1111/j.1540-8159.2012.03411.x.CrossRefPubMed

64.

Brignole M, Vardas P, Hoffmann E, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace. 2009;11:67–87. https://doi.org/10.1093/europace/eup097.CrossRef

65.

Giancaterino S, Lupercio F, Nishimura M, et al. Current and future of insertable cardiac monitors. JACC Clin Electrophysiol. 2018;4(11):1383–96. https://doi.org/10.1016/j.jacep.2018.06.001.CrossRefPubMed

66.

Brignole M, Moya A, de Lange FJ, et al. ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883–948. https://doi.org/10.1093/eurheartj/ehy037.CrossRefPubMed

67.

Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017;70(5):e39–110. https://doi.org/10.1016/j.jacc.2017.03.003.CrossRefPubMed

68.

Steinberg JS, Varna N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. 2017;14:e55-96. https://doi.org/10.1016/j.hrthm.2017.03.038.CrossRefPubMed

69.

Krahn AD, Klein GJ, Yee R, et al. Randomized assessment of syncope trial: conventional diagnostic versus a prolonged monitoring strategy. Circulation. 2001;104:46–51. https://doi.org/10.1161/01.cir.104.1.46.CrossRefPubMed

70.

Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace. 2011;13:262–9. https://doi.org/10.1093/europace/euq418.CrossRefPubMed

71.

Solbiati M, Costantino G, Casazza G, et al. Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope. Cochrane Database Syst Rev. 2016;4:CD011637. https://doi.org/10.1002/14651858.CD011637.pub2.CrossRefPubMed

72.

Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–9. https://doi.org/10.1056/NEJMoa1105575.CrossRefPubMed

73.

Verma A, Cairns JA, Mitchell LB, et al. 2014 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30:1114–30. https://doi.org/10.1016/j.cjca.2014.08.001.CrossRefPubMed

74.

Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmias burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2:474–80. https://doi.org/10.1161/CIRCEP.109.849638.CrossRefPubMed

75.

Glotzer TV, Hellkamp AS, Zimmermann J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the Mode Selection Trial (MOST). Circulation. 2003;107:1614–9. https://doi.org/10.1161/01.CIR.0000057981.70380.45.CrossRefPubMed

76.

Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38:1339–44. https://doi.org/10.1093/eurheartj/ehx042.CrossRefPubMed

77.

Mahajan R, Perera T, Elliott AD, et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J. 2018;39:1409–15. https://doi.org/10.1093/eurheartj/ehx731.CrossRef

78.••

Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021;398(10310):1507–16. https://doi.org/10.1016/S0140-6736(21)01698-6. This study was conducted in a large population comparing ILR to usual care diagnostic for detection of AF in patients at risk of stroke.CrossRefPubMed

79.••

Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Egl J Med. 2014;370:2478–86. https://doi.org/10.1056/NEJMoa1313600. One of the most important RCT for the detection of subclinical AF after cryptogenic stroke or TIA, randomizing ILR and standard of care monitoring.CrossRef

80.

Brachmann J, Morillo CA, Sanna T, et al. Uncovering atrial fibrillation beyon short-term monitoring in cryptogenic stroke patients: three-years results from the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. Circ Arrhythm Electrophysiol. 2016;9:e003333. https://doi.org/10.1161/CIRCEP.115.003333.CrossRefPubMed

81.

Ziegler PD, Rogers JD, Fereira SW, et al. Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population. Int J Cardiol. 2017;244:175–9. https://doi.org/10.1016/j.ijcard.2017.06.039.CrossRefPubMed

82.

Albers GW, Bernstein RA, Brachmann J, et al. Heart rhythm monitoring strategies of cryptogenic stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. J Am Heaert Assoc. 2016;5:e002944. https://doi.org/10.1161/JAHA.115.002944.CrossRef

83.

Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236. https://doi.org/10.1161/STR.0000000000000024.CrossRefPubMed

84.•

Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale of smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381:1909–17. https://doi.org/10.1056/NEJMoa1901183. One of the most important trails of wearables for detecting atrial fibrillation.CrossRefPubMedPubMedCentral

85.

Pevnick JM, Birkeland K, Zimmer R, et al. Wearable technology for cardiology: an update and framework for the future. Trends Cardiovasc Med. 2018;28:144–50. https://doi.org/10.1016/j.tcm.2017.08.003.CrossRefPubMed

86.

Silva-Cardoso J, Juanatey JRG, Comin-Colet J, et al. The future of telemedicine in the management of heart failure patients. Card Fail Rev. 2021;7:e11. https://doi.org/10.15420/cfr.2020.32.CrossRefPubMedPubMedCentral

Titel: Remote Monitoring of Cardiac Implantable Electronic Devices: What is the Evidence?
verfasst von: Adrian Reinhardt
Rodolfo Ventura
Publikationsdatum: 26.01.2023
Verlag: Springer US
Erschienen in: Current Heart Failure Reports / Ausgabe 1/2023
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-023-00586-1

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Remote Monitoring of Cardiac Implantable Electronic Devices: What is the Evidence?

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Heart Failure and Multimorbidity in Asia

Myocardial Metabolism in Heart Failure

Cardiac Involvement in Mitochondrial Disorders

Spot Urinary Sodium Measurements: the Future Direction of the Treatment and Follow-up of Patients with Heart Failure

Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure

Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie